This is exciting news!

LOS ANGELES and STUDIO CITY, Calif., Oct. 22, 2026 /PRNewswire/ — Today, the International Myeloma Foundation (IMF) announced the launch of the US Myeloma Network (USMN) — a first-of-its-kind national clinical research network designed to accelerate the prevention and cure of multiple myeloma by advancing scientific discovery, expanding access to clinical trials, and ensuring more patients benefit from breakthrough therapies. Johnson & Johnson joins this initiative as the network’s first industry collaborator. The USMN will focus on clinical trials with the potential to change clinical practice across care settings, accelerating the delivery of innovative therapies and new treatment approaches to patients.

The USMN connects leading academic centers, community oncology practices and industry partners through a coordinated national infrastructure designed to streamline trial activation, reduce operational barriers, expand equitable access to clinical trials, and accelerate the development of more effective therapies across the continuum of myeloma care – from prevention and early intervention through relapsed and refractory disease.

“The future of myeloma depends on our ability to bring scientific innovation to patients more quickly and more equitably,” said S. Vincent Rajkumar, MD, Mayo Clinic, Chairperson of the International Myeloma Foundation. “The US Myeloma Network creates an unprecedented opportunity to unite investigators across the country through a coordinated research infrastructure that accelerates clinical trials, expands patient participation, and advances the discoveries that will ultimately lead to the prevention—and one day the cure—of multiple myeloma.”